Cantor Fitzgerald reaffirmed its rating for Immunocore on July 20, 2026.
3 reports, 2 independent
Updated Aug 16
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald reaffirmed its rating for Immunocore on July 20, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Immunocore
UK business
Nothing else this week.
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
- Cantor Fitzgerald reiterated an Overweight rating for aTyr Pharma on August 20, 2025.
- Cantor Fitzgerald hosted a healthcare conference on September 8, 2026.
- Cantor Fitzgerald set a neutral rating on Merck & Co., Inc. on September 12, 2026.